All In Biotech

Drug Trial Radar · NCT07256782

A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors

A Phase Ib/II, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administration of QLC5508 in Combination With Other Anti-tumor Agents in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

444

Planned (sponsor's estimate)

Start

Oct 24, 2025

Primary completion

Oct 2026

Study completion May 2028

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Dec 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

QLC5508 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of QLC5508 in combination with other anti-cancer agents in patients with advanced solid tumor patients.

Conditions

  • Advanced Solid Tumor

Interventions

  • QLC5508Drug

    2.4 mg/kg and 2.0 mg/kg, Q3W/Q2W,administered as an IV infusion

  • QL1706Drug

    5 mg/kg ,Q3W,administered as an IV infusion

  • Cisplatin/ CarboplatinDrug

    Cisplatin(75 mg/m2; Q3W) / Carboplatin(AUC 5 mg/mL/min; Q3W),administered as an IV infusion

  • QL2107Drug

    200 mg, Q3W,administered as an IV infusion

  • PaclitaxelDrug

    175 mg/m2, Q3W,administered as an IV infusion

  • 5-fluorouracil (5-FU)Drug

    800 mg/m2,Q3W(arm:QLC5508, QL2107 and 5-FU),administered as an IV infusion;1200 mg/m2, Q2W(arm:QLC5508, Oxaliplatin, 5-FU,and leucovorin),administered as an IV infusion

  • OxaliplatinDrug

    30 mg/m2, Q2W,administered as an IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) for combination-treatments (Phase Ib)Time frame: Up to day 21 (Q3W combination) or day 28 (Q2W combination) from the first dose
  2. Recommended Phase II Dose (RP2D) for combination-treatments (Phase Ib)Time frame: Up to day 21 (Q3W combination) or day 28 (Q2W combination) from the first dose
  3. Objective response rate (ORR) determined by investigators (Phase II)Time frame: Approximately 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East Hospital

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.